Early occurrence of pseudocysts in acute pancreatitis - A multicenter international cohort analysis of 2275 cases by Szakó, Lajos et al.
lable at ScienceDirect
Pancreatology xxx (xxxx) xxxContents lists avaiPancreatology
journal homepage: www.elsevier .com/locate/panEarly occurrence of pseudocysts in acute pancreatitis e A multicenter
international cohort analysis of 2275 cases
Lajos Szako a, b, Noemi Gede a, c, Alex Varadi a, c, Benedek Tinusz a, b, f, Nora V€orhendi a, b,
Dora Mosztbacher a, b, d, e, Aron Vincze f, Tamas Takacs g, Laszlo Czako g, Ferenc Izbeki h,
Laszlo Gajdan h, Veronika Dunas-Varga h, Jozsef Hamvas i, Maria Papp j,
Krisztina Eszter Feher j, Marta Varga k, Artautas Mickevicius l, Imola T€or€ok m,
Klementina Ocskay a, b, Mark Felix Juhasz a, b, Szilard Vancsa a, b, Nandor Faluhelyi n,
Orsolya Farkas n, Attila Miseta o, Andras Vereczkei p, Alexandra Miko a, b,
Peter Jen}o Hegyi a, b, Andrea Szentesi a, b, g, Andrea Parniczky a, b, e, q, Balint Er}oss a, b, 1,
Peter Hegyi a, b, g, r, s, *, 1
a Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary
b Szentagothai Research Center, Medical School, University of Pecs, Pecs, Hungary
c Institute of Bioanalysis, Medical School, University of Pecs, Hungary
d First Department of Paediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary
e Doctoral School of Theoretical Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary
f First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary
g First Department of Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary
h Szent Gy€orgy Teaching Hospital of County Fejer, Szekesfehervar, Hungary
i Bajcsy-Zsilinszky Hospital, Budapest, Hungary
j Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
k Department of Gastroenterology, Dr. Rethy Pal Hospital of County Bekes, Bekescsaba, Hungary
l Vilnius University Hospital Santaros Clinics, Clinics of Abdominal Surgery, Nephro-urology and Gastroenterology, Faculty of Medicine, Vilnius University,
Vilnius, Lithuania
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Background: Pseudocysts being the most frequent local complications of acute pancreatitis (AP) have
substantial effect on the disease course, hospitalization and quality of life of the patient. Our study aimed
to understand the effects of pre-existing (OLD-P) and newly developed (NEW-P) pseudocysts on AP.
Methods: Data were extracted from the Acute Pancreatitis Registry organized by the Hungarian
Pancreatic Study Group (HPSG). 2275 of 2461 patients had uploaded information concerning pancreatic
morphology assessed by imaging technique. Patients were divided into “no pseudocyst” (NO-P) group,
“old pseudocyst” (OLD-P) group, or “newly developed pseudocyst” (NEW-P) groups.
Results: The median time of new pseudocyst development was nine days from hospital admission and
eleven days from the beginning of the abdominal pain. More NEW-P cases were severe (15.9% vs 4.7% in
the NO-P group p < 0.001), with longer length of hospitalization (LoH) (median: 14 days versus 8 days,
p < 0.001), and were associated with several changed laboratory parameters. OLD-P was associated withMedicine, University of Pecs,
B.V. on behalf of IAP and EPC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
. Varadi et al., Early occurrence of pseudocysts in acute pancreatitis e A multicenter international
, https://doi.org/10.1016/j.pan.2021.05.007
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Pancreatic local complicationmale gender (72.2% vs. 56.1%, p ¼ 0.0014), alcoholic etiology (35.2% vs. 19.8% in the NO-P group), longer
hospitalization (median: 10 days, p < 0.001), a previous episode of AP (p < 0.001), pre-existing diagnosis
of chronic pancreatitis (CP) (p < 0.001), current smoking (p < 0.001), and increased alcohol consumption
(unit/week) (p ¼ 0.014).
Conclusion: Most of the new pseudocysts develop within two weeks. Newly developing pseudocysts are
associated with a more severe disease course and increased length of hospitalization. Pre-existing
pseudocysts are associated with higher alcohol consumption and smoking. Because CP is more
frequently associated with a pre-existing pseudocyst, these patients need closer attention after AP.
© 2021 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute pancreatitis (AP) is one of the most common acute
gastroenterological conditions, with a prevalence of 6e18.6% [2,3]
in acute pancreatitis and between 20 and 40% in chronic inflam-
mation [4], which requires acute hospitalization [5]; however,
several unanswered questions remain [6]. Although most AP cases
are mild, local or systemic complications develop in 20e30% of
cases, often necessitating interventions [7]. According to the
revised Atlanta classification, the most common form of late local
complication is the pancreatic pseudocyst, which usually occurs
four weeks after the disease onset. It is described as a homogenous
and capsulated fluid collection on the pancreas without necrotic
tissue [8].
Many risk factors have been associated with pseudocyst for-
mation, but predictive factors remain underestimated. Akgül et al.
found that a lower serum calcium level may be a predictive factor
for developing pancreatic pseudocysts after AP attack [9]. The
prospective multicenter observational study of Cui et al., in 2013
concluded that lactate dehydrogenase (LDH) after 48 h of AP's onset
seemed to be a risk factor of pseudocyst formation. Other findings
were that age, CRP (48 h), and alcohol etiology appeared to be risk
factors for pancreatic fluid collections [10]. An important limitation
of cohort studies describing pancreatic pseudocysts that they do
not investigate the differences between pre-existing (OLD-P) or
newly developed (NEW-P) pseudocysts [11,12], causing difficulties
in data interpretation. Furthermore, most of the cohort studies
focus on the treatment of pseudocyst, but not on the risk factors of
pseudocyst development, or the pseudocyst's impact on the dis-
ease's clinical outcome.
Here we provide one of the most extensive and most detailed
analysis of pseudocyst development, helping clinicians to under-
stand the relevant risks factors and clinical characteristics of both
pre-existing and newly developed pancreatic pseudocyst in AP.
Materials and Methods
Data source
Data were collected from the multicenter international AP reg-
istry run by the Hungarian Pancreatic Study Group (HPSG). At the
time of data extraction (October 2019) our registry contained 2461
AP cases collected from 34 hospitals of 13 countries between 2012
and 2019. (Supplementary Table 1, Supplementary Figure 1).
Importantly, all patients were diagnosed with AP based on the 2/3
rules described in the guidelines [13,14], whereas the severity of AP
was determined using the revised Atlanta classification [8].
Data quality
The accuracy of acquired data was ensured by a four-level
quality monitoring system involving medical administrative2
personnel and gastroenterologist specialists, as described in our
earlier published cohort analyses [7,15e20]. 105381 of 125125
variables were uploaded, which resulted in 84% available data for
analysis (Supplementary Table 2).
Identification of pseudocysts
Altogether 2275 AP cases contained valuable information on
pancreatic morphology. Medically trained researchers reviewed
the prospectively collected reports of abdominal imaging, but not
the images themselves, for the presence of pancreatic pseudocysts.
These imaging modalities included abdominal ultrasonography,
computer tomography (CT), endoscopic ultrasound (EUS), or mag-
netic resonance cholangiopancreatography (MRCP). The identifi-
cation of pseudocysts was based on the morphological
recommendations of the revised Atlanta classification [8]. Gener-
ally, the fluid and necrotic collections were categorized into four
groups, namely acute pancreatic fluid collection (APFC), acute
necrotic fluid collection (ANFC), pancreatic pseudocyst, andwalled-
off necrosis (WON). Fig. 1 describes the used morphological criteria
for the diagnosis, along with examples of imaging examinations
from our center (University of Pecs, Medical School) (Fig. 1). We
included only pancreatic pseudocysts in our analysis.
Group formation and patients’ characteristics
Patients where the latest imaging examinations of AP showed
no pseudocyst formation were included in the “no pseudocyst”
(NO-P) group. Patients with pseudocyst-positive imaging exami-
nation during the first four days of hospital stay were assigned to
the “old pseudocyst” (OLD-P) group. In contrast, patients with a
negative imaging examination in the first four days of hospital stay
and positive imaging during hospital stay were assigned to the
“new pseudocyst” (NEW-P) group.
Representativeness of the cohort
The analyzed cohort's representativeness was evaluated by
comparing the following characteristics between the full cohort of
2461 patients and the cohort of 2245 patients, with data on
pancreatic morphology included in the analysis. No significant
differences were found between the two groups in terms of age,
gender, severity, length of hospitalization, and pancreatitis etiology.
For the detailed analysis of representativity, see Supplementary
Figure 2.
Statistical analysis
Statistical analysis was performed using the following statistical
tests: for discrete and non-normally distributed continuous vari-
ables Kruskal-Wallis rank-sum test with a significance level of 0.05,
followed by Dunn's post hoc test with Holm-Sídak p-value
Fig. 1. Computer tomography (CT) images and description for morphological diagnosis.
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Whereas for categorical variables, the incidence in each group was
determined. In these cases, to analyze the relations between vari-
ables, Chi-square test or Fisher's exact test was conducted. A p-
value of less than 0.05 (0.05) was determined as statistically
significant. All analyses were performed using R studio 1.3.1073 (R
Foundation for Statistical Computing, Vienna, Austria) [21], and
Dunn's tests were performed using the package dunn.test [22].3
Ethical approval for the clinical study
The study was approved by the Scientific and Research Ethics
Committee of the Medical Research Council (22254-1/2012/EKU).
All participants provided written, informed consent for the
enrollment to the registry.
Results
From the 2275 patients, 2054 were included in the NO-P group,
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the NEW-P group. 28.4% of patients had one, whereas 71.6% had at
least two imaging examinations during the disease course. 33.33%
of the patients in the OLD-P group and 19.21% of the patients in the
NEW-P group had only ultrasound as an imaging examination,
while the rest was diagnosed with computer tomography.
OLD-P is associated with male gender and alcoholic etiology
Patients in the OLD-P group were predominantly male
compared with the NO-P groups (72.2% vs. 56.1%, p ¼ 0.0014)
(Fig. 2A). The average age was 56.1 ± 17.1 years in the NO-P and
55.0 ± 13.7 years in the OLD-P (Fig. 2B), without a statistically
significant difference (p¼ 0.1852). Alcoholic etiologywas dominant
in the OLD-P group (35.2% vs. 19.8%), while biliary etiology was less
common (22.2% vs. 41.8%) compared to the NO-P group. Detailed
results regarding the etiology are presented in Fig. 2C.
NEW-P is not associated with gender or etiology
Gender did not differ significantly comparing NO-P and NEW- P
(56.1% vs 64.6%, p ¼ 0.0929). There was no significant difference
regarding age between NO-P and NEW-P (56.1 ± 17.1 years vs
59.6 ± 13.2 years respectively, p¼ 0.0300) (Fig. 2B). In the NO-P and
NEW-P groups, the distribution of etiologic factors was not
different from the entire cohort (Fig. 2C).
More than half of the NEW-P can be diagnosed in the first two
weeks
In our cohort, the median of the first detection of NEW-P was on
day 9 (IQR1-3: 7e15) calculated from admission, whereas 11 days
(IQR 1e3: 7e16) from the beginning of the abdominal pain
(Fig. 3A), although it should be highlighted that, the data quality
regarding the duration of abdominal pain is 70%Fig. 2. Demographic data A) Gender distribution B) Age C) Etiology. Statistically significant d
P: old pseudocyst group, NEW-P: new pseudocyst, ERCP: endoscopic retrograde cholangiop
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NEW-P worsens the disease course and is associated with longer
hospitalization
Since a NEW-P must be considered moderate AP, it is not sur-
prising that no mild AP was detected in the NEW-P group. A
significantly larger proportion of patients experienced moderate
and severe course of AP compared to the NO-P group (p < 0.001)
(Fig. 3C). Patients were hospitalized for significantly longer the
NEW-P (median: 14 days, IQR 1e3: 8e22, p < 0.001) group
compared to the NO-P group (median: 8 days, IQR 1e3: 5e11 days)
(Fig. 3D). Concerning mortality, we could not detect statistically
significant differences between (p ¼ 0.1486). Still, mortality was
5.2% in the NEW-P group versus 2.8% in the NO-P group (Fig. 3B).
OLD-P is also associated with undesirable outcomes regarding
hospitalization and disease course
OLD-P was significantly associated with moderate severity
compared to the NO-P group (56.5% and 19.33%, respectively,
p < 0.001). (Fig. 3C). Patients were hospitalized for significantly
longer in the OLD-P group (median: 10 days, IQR 1e3: 6.8e16.2
days, p < 0.001) compared to the NO-P group (median: 8 days, IQR
1e3: 5e11 days) (Fig. 3D). Mortality did not differ significantly
among the OLD and NO-P group (p ¼ 0.7671)Previous pancreatic inflammation, chronic pancreatitis, current
smoking, and increased alcohol consumption are risk factors of OLD-
P
A previous episode of AP (60% vs 25.3%, p < 0.001), pre-existing
diagnosis of CP (24.8% vs 4.9% p < 0.001), current smoking (49.1% vs
30.5%, p < 0.001), and increased weekly alcohol consumption
(800.9 g/week vs 495.9 g/week, p ¼ 0.014) were significantly
associated with OLD-P compared to NO-P. At the same time, we
could not detect significant differences comparing NO-P and OLD-Pifferences are indicated with *. AP: acute pancreatitis, NO-P: no pseudocyst group, OLD-
ancreatography, SD: standard deviation.
Fig. 3. Outcomes A) first day of new cyst detection from admission and from the beginning of the abdominal pain, B) mortality, C) severity: percentages are indicated in the columns
referring to each severity rank, D) length of hospitalization. Statistically significant differences are indicated with *. NO-P: no pseudocyst group, OLD-P: old pseudocyst group, NEW-
P: new pseudocyst.
Fig. 4. Medical history. A) Previous acute pancreatitis (AP) episodes B) Previous chronic pancreatitis (CP) episodes C) Current smoking D) Former smoking E) Previous diabetes
mellitus F) Alcohol consumption. Percentages are indicated, as well as the included number (n) of patients in the analysis. Statistically significant differences are indicated with *.
NO-P: no pseudocyst group, OLD-P: old pseudocyst group, NEW-P: new pseudocyst, AP: acute pancreatitis, CP: chronic pancreatitis.
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(p ¼ 0.2257) (Fig. 4).
Former smoking is associated with newly developing pseudocyst
Former smoking was associated with NEW-P compared to NO-P.
(38.5% vs 25.4% p ¼ 0.029). Differences were not found comparing
NO-P and NEW-P regarding diabetes mellitus (p ¼ 0.3359), alcohol
consumption (p ¼ 0.2806), current smoking (p ¼ 0.7497), previous
AP episodes (p ¼ 0.5294) and previous CP episodes (p ¼ 0.8908)
(Fig. 4).
On admission abdominal guarding, vomiting, increased systolic and
diastolic blood pressure are risk factors of NEW-P
Significant difference was found comparing NEW-P with NO-P
considering abdominal guarding (25.7% vs 16.3%, p ¼ 0.0155),
increased diastolic blood pressure (88.38 ± 15.06 mmHg vs
84.14 ± 14.03 mmHg, p ¼ 0.051), increased systolic blood pressure
(150.89 ± 27.28 mmHg vs 140.70 ± 22.98 mmHg, p ¼ 0.0035) and
vomiting (70% vs 56.8%, p ¼ 0.0088), while nausea (p ¼ 0.4383),
subfebrility/fever (p¼ 0.8261), abdominal tenderness (p¼ 0.2548),
abdominal pain length (p ¼ 0.3788), abdominal pain intensity
(p ¼ 0.1917), heart rate (p ¼ 0.2027) did not differ significantly.
On admission clinical parameters did not differ between NO-P and
OLD-P
We did not find statistical difference between NO-P and OLD-P
regarding nausea (p ¼ 0.0752), vomiting (p ¼ 0.0633), sub-
febrility/fever (p ¼ 1.0000), abdominal tenderness (p ¼ 0.7814),
abdominal guarding (p ¼ 0.5991), abdominal pain intensity
(p ¼ 0.2209), abdominal pain length (p ¼ 0.0775), heart rate
(p ¼ 0.3411), diastolic blood pressure (p ¼ 0.1331), and systolic
blood pressure (p < 0.2844) (Fig. 5).
Lower levels of on-admission amylase and lipase were found in
patients with OLD-P
Considering on admission laboratory parameters, amylase, and
lipase levels were significantly lower in the OLD-P group than in the
NO-P group (770.6 ± 989.3 U/L vs. 1094 ± 1129 U/L, p ¼ 0.0003)
(Fig. 6); however, this difference disappeared after excluding those
patients who were suffering from CP or recurrent AP
(Supplementary Figure 3).
Pancreatic enzyme levels were not associated with NEW-P
Amylase (p ¼ 0.4142) and lipase (p ¼ 0.4001) did not differ
significantly between NO-P and NEW-P patients (Fig. 6).
Decreased red blood cell parameters and increased thrombocyte
counts were found in the OLD-P
On admission red blood cell count (4.417 ± 0.6212 T/L vs.
4.699 ± 0.6231 T/L, p ¼ 0.0002) (Fig. 7D), hemoglobin
(135.6 ± 09.90 g/L vs. 142.9 ± 18.9 g/L, p ¼ 0.0017) (Fig. 7E), he-
matocrit (39.88 ± 5.363% vs. 41.65 ± 5.079%, p ¼ 0.0045) (Fig. 7B)
levels were lower, while thrombocyte count (305 ± 128.7G/L vs.
249.6 ± 88.73G/L p ¼ 0.0001) (Fig. 7A) was increased in the OLD-P
group compared to NO-P group.
OLD-P is associated with lower BMI, cholesterol, and glucose levels
Regarding clinical parameters on admission, patients in the6
OLD-P group had significantly lower BMI (25.84 ± 6.63 kg/m2)
compared to the NO-P group (28.09 ± 5.95 kg/m2, p < 0.001)
(Fig. 5E). Glucose (7.436 ± 2.433 mmol/L vs. 8.338 ± 3.569 mmol/L,
p ¼ 0.0178) (Fig. 7G) and cholesterol (4.593 ± 3.82 mmol/L vs.
5.465 ± 4.02 mmol/L, p ¼ 0.0081) (Fig. 7F) levels were significantly
lower in the OLD-P group comparing it to NO-P.
On admission BMI and cholesterol levels were not associated with
NEW-P
Significant differences were not found comparing NO-P and
NEW-P in terms of on admission BMI (p ¼ 0.3154) (Fig. 7E) and
cholesterol (p ¼ 0.3179) (Fig. 7F).
On admission calculated averages of lactate dehydrogenase (LDH),
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
total bilirubin, direct bilirubin, and gamma-glutamyl transferase
(gamma GT) were lower whereas, the average of C reactive protein
(CRP) levels was higher in the OLD-P group
Lactate-dehydrogenase (420.6 ± 258.7 (U/L vs. 486.2 ± 315.5 U/
L, p ¼ 0.01), AST (68.69 ± 117.7 U/L vs. 156.2 ± 208.1 U/L, p < 0.001),
ALT (69.03 ± 141.2 U/L vs. 154.7 ± 199.6 U/L, p < 0.001), total bili-
rubin (27.83 ± 50.67 mmol/L vs. 35.81 ± 39.28 mmol/L, p ¼ 0.0005),
direct bilirubin (15.04 ± 27.3 mmol/L vs 27.79 ± 35.27 mmol/L,
p ¼ 0.003) and GGT (245.2 ± 372.2 U/L vs. 362.9 ± 489.8 U/L,
p < 0.001) were lower in the OLD-P as the result of etiological
difference. CRP (78.48 ± 82.94 mg/L vs. 49.97 ± 75.32, mg/L
p < 0.001) levels were higher in the OLD-P group than the NO-P
group (Figs. 7e8).
On admission liver function tests and C-reactive protein did not
differ comparing NEW-P and NO-P
NEW-P did not differ from NO-P in terms of AST (p ¼ 0.3423),
ALT (p ¼ 0.2928), gamma-GT (p ¼ 0.2737) and CRP (p ¼ 0.0826)
(Fig. 8).
Increased inflammatory parameters, hemoglobin, hematocrit,
glucose, blood urea nitrogen, LDH and creatinine levels are
associated with NEW-P compared to NO-P
Patients in the NEW-P group had significantly higher on
admission white blood cell (WBC) count (14.57 ± 4.411 G/L vs.
12.89 ± 4.956 G/L, p ¼ 0.0001), hemoglobin (150.1 ± 20.38 g/L vs.
142.9 ± 18.9 g/L, p ¼ 0.0001), hematocrit (43.08 ± 5.445%, vs.
41.65 ± 5.079%, p ¼ 0.0043), glucose (9.717 ± 3.633 mmol/L vs.
8.338 ± 3.569mmol/L, p < 0.001), blood urea nitrogen (7.07 ± 3.702
vs. 6.313 ± 3.837, p¼ 0.0125), lactate dehydrogenase (592.2 ± 319.5
vs. 486.2 ± 315.5, p ¼ 0.0002) and creatinine levels
(89.021 ± 6.879 mmol/L vs. 75.426 ± 5.890 mmol/L, p < 0.0125)
(Figs. 7e8), while also higher levels of maximum CRP
(167 ± 104.3 mg/L vs. 147.8 ± 118.3 mg/L, p ¼ 0.0141) and WBC
(18.41 ± 7.023 G/L vs. 14.38 ± 6.651 G/L, p < 0.001) levels compared
to NO-P group (Suppl. Fig. 3). On admission thrombocyte count did
not differ comparing NO-P and NEW-P (0.1877) (Fig. 7A).
On admission kidney function parameters and white blood cell
count did not differ between NO-P and OLD-P groups
OLD-P did not differ from NO-P considering on admission WBC
count (p ¼ 0.3184) (Fig. 7B), blood urea nitrogen (p ¼ 0.0322)
(Fig. 7B), creatinine levels (p ¼ 0.0322) (Fig. 7H) and maximum
WBC count (p ¼ 0.0429) (Suppl. Fig. 3).
Fig. 5. On admission clinical parameters A) Abdominal pain length B) Abdominal guarding C) Abdominal pain intensity D) Blood pressure E) Body-mass index (BMI) F) Subfebrility/
fever G) Nausea H) Heart rate (/min) I) Vomiting. Percentages are indicated, as well as the included number (n) of patients in the analysis. Statistically significant differences are
indicated with *. AP: acute pancreatitis, NO-P: no pseudocyst group, OLD-P: old pseudocyst group, NEW-P: new pseudocyst.
Fig. 6. On admission laboratory parameters I.: A) on admission amylase, B) on admission lipase. Statistically significant differences are indicated with *. NO-P: no pseudocyst group,
OLD-P: old pseudocyst group, NEW-P: new pseudocyst.
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OLD-P
Concerning the complications, OLD-P was associated compared
to NO-P with a higher incidence of the acute pancreatic fluid
collection (APFC) (38.9% vs. 19% p < 0.001), ascites (34.45% vs. 14.1%
p < 0.001), systemic complication (13.15% vs. 7.8% p ¼ 0.0113) and7
respiratory failure (9.3% vs. 5.2% p ¼ 0.0182), while pleural fluid
(p ¼ 0.7975), necrosis (p ¼ 0.9062), heart failure (p ¼ 0.6470), and
renal failure (p ¼ 0.4732) did not differ.Systemic and local complications are associated with NEW-P too
NEW-P was associated with higher rate of APFC (70.8% vs. 19%
Fig. 7. On admission laboratory parameters II.: Hematological parameters, cholesterol, glucose, kidney functions. Number (n) of patients included in the analysis are indicated.
Statistically significant differences are indicated with *. NO-P: no pseudocyst group, OLD-P: old pseudocyst group, NEW-P: new pseudocyst, Htc: hematocrit, WBC: white blood cell,
RBC: red blood cell, HGB: hemoglobin, BUN: blood urea nitrogen.
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tions (21.2 vs. 7.8% p ¼ 0.0245) compared to NO-P, while there was
no difference considering pleural fluid (p ¼ 0.7939), ascites
(p ¼ 0.4995), respiratory failure (p ¼ 0.4995), heart failure
(p ¼ 0.0495) and renal failure (p ¼ 0.0592) (Fig. 9).
One in four patients with OLD-P, whereas one in six patients with
NEW-P required interventions
Interventions, such as endoscopic, percutaneous, and surgical
drainage on pancreatic pseudocysts, were performed in 44 cases in
our cohort. There were no significant differences comparing OLD-P
and NEW-P regarding any intervention (p ¼ 0.3124), surgical
intervention (p ¼ 0.7058), percutaneous intervention (p ¼ 1.0000),
endoscopic intervention (p ¼ 0.7639) comparing the two groups
(Fig. 10).
Further on admission laboratory parameters did not differ among
NEW-P and NO-P
Differences were not found comparing NO-P and NEW-P
considering on admission calcium (p ¼ 0.2945), potassium
(p ¼ 0.4815), total protein (p ¼ 0.4635), albumin (p ¼ 0.4532),
estimated glomerular filtration rate (p ¼ 0.1021), tryglyceride
(p ¼ 0.2392), direct bilirubin (p ¼ 0.0713), alkaline phosphatase
(p¼ 0.0489), procalcitonine (p¼ 0.6488), amylase (p¼ 0.4535) and
lipase (p ¼ 0.3506) including only AP cases.8
Further on admission laboratory parameters did not differ among
OLD-P and NO-P
OLD-P did not differ from NO-P regarding on admission calcium
(p ¼ 0.2201), potassium (p ¼ 0.3090), total protein (p ¼ 0.6143),
albumin (p ¼ 0.0950), estimated glomerular filtration rate
(p ¼ 0.0556), tryglyceride (p ¼ 0.1400), alkaline phosphatase
(p¼ 0.0667), procalcitonine (p¼ 0.7398), amylase (p¼ 0.0989) and
lipase (p ¼ 0.0358) including only AP cases.
Discussion
The most intriguing finding of our results is that pancreatic
pseudocysts can be diagnosed earlier than previously suggested.
The revised Atlanta classification of 2012 does not explicitly state
that pseudocysts can only be diagnosed four weeks after the onset
of pancreatitis; it only implies that it occurs most commonly after
the mentioned time interval [8]). Our analysis showed that at least
half of the pancreatic pseudocysts could be diagnosed in the first
twoweeks following the radiological morphology suggested by the
same classification. Therefore, we recommend the nonmandatory
use of this timeframe.
Delaying interventions based on the initially late diagnosis
might be one reason why new pseudocysts were associated with a
longer length of hospital stay. However, the association between
LoH and OLD-P highlights the effect of pseudocyst itself on the
severity, eventually resulting in longer hospitalization. While the
Fig. 8. On admission laboratory parameters III.: C-reactive protein (CRP) and liver functions. Number (n) of patients included in the analysis are indicated. Statistically significant
differences are indicated with *. NO-P: no pseudocyst group, OLD-P: old pseudocyst group, NEW-P: new pseudocyst, CRP: C-reactive protein, GGT: gamma-glutamyl transferase,
LDH: lactate dehydrogenase, ASAT/GOT: Aspartate aminotransferase/glutamic oxaloacetic transaminase, ALAT/GPT: alanine aminotransferase/glutamate pyruvate transaminase,
TBIL: total bilirubin.
Fig. 9. Systemic and local complications. A) heart failure, B) respiratory failure, C) systemic organ failure, D) necrosis, E)acute pancreatic fluid collection (APFC), F) Ascites. Per-
centages are indicated as well as the number (n) of patients included in the analysis. Statistically significant differences are indicated with *. AP: acute pancreatitis, NO-P: no
pseudocyst group, OLD-P: old pseudocyst group, NEW-P: new pseudocyst.
L. Szako, N. Gede, A. Varadi et al. Pancreatology xxx (xxxx) xxx
9
Fig. 10. Management of the pseudocysts. A) Any intervention B) Percutaneous intervention C) Endoscopic intervention D) Surgical intervention. Percentages are indicated as well as the
number (n) of patients included in the analysis. AP: acute pancreatitis, OLD-P: old pseudocyst group, NEW-P: new pseudocyst.
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ence, an increased death rate was observed in the OLD-P and NEW-
P groups compared to the NO-P group, which might imply type II
statistical error due to the low number of cases. Furthermore, the
higher rate of systemic organ failures in both groups compared to
the NO-P patients can also lead to increased mortality.
The associations of newly developing pseudocyst, former
smoking, and altered laboratory parameters are suggested as risk
factors for cyst development by our analysis. They could be used as
motives to perform additional imaging examinations to diagnose
fluid collections.
The toxic effects of alcohol consumption, as well as smoking and
their role in cyst formation, should be highlighted, which associa-
tion is also presented in the larger proportion of alcoholic etiology
in the OLD-P group, while former smoking also plays an important
role in NEW-P. Alcoholic etiology was also highlighted by Cui et al.
regarding cyst formation. Furthermore, a meta-analysis from
Sharanya et al. found that alcoholic etiology, male gender, and
smoking are risk factors for chronic pancreatitis, which is the
ground of pancreatic pseudocyst formation [23]. The association of
alcoholic etiology and cyst formation was also found by an Indian
prospective cohort study, where 65.6% of the patients had alcohol
consumption in their medical history [24]. A multicenter and
multinational (Germany, Italy, and the United States of America)
study from Lankisch et al. also proved that alcohol consumption is
associated with cyst formation (p ¼ 0.0008) [25]. This finding is
also supported by a retrospective analysis from China, where
alcoholic etiology (p ¼ 0.031) and chronic pancreatitis (p ¼ 0.006)
were identified as risk factors for cyst formation. The more pseu-
docysts associated with alcohol consumption are probably due to
the direct toxic effects of these factors on acinar and ductal cells.
Both agents cause elevated intracellular calcium, adenosine10triphosphate (ATP) level, and membrane protein transition pore
(MPTP) inhibition [26e28], leading the cell to necrosis in both
exocrine cell types [29e31]. This can disrupt the epithelial barrier's
integrity, causing leakage of ductal fluid to the peri-and intra-
pancreatic space.
Former inflammatory episodes and chronic inflammations of
the pancreas were associated with an increased risk of old pseu-
docysts. Our result is in accordance with the South Korean cohort
study, where the overall incidence of pseudocyst after acute or
acute-on-chronic pancreatitis was 18.3% (n ¼ 74/405) [32]. Pseu-
docysts developed much more frequently in patients with under-
lying chronic pancreatitis than in patients with acute pancreatitis
(41.5% vs. 14.6%, p < 0.001).
In our study, NEW-P was associated with abdominal guarding,
vomiting and increased blood pressure, and more severe disease
outcomes. Unfortunately, our cohort analysis did not allow us to
investigate the cause-relationship in these associations.
We have earlier reported that the cluster of conditions called
metabolic syndrome, most importantly diabetes mellitus, hyper-
tension, and obesity have a detrimental effect on the disease course
of pancreatitis [17]. On the other hand, we found that a lower BMI is
a sensitive indicator of malnutrition in chronically affected
pancreatic patients with old pseudocysts.
The malnourishment is also reflected by the on-admission lab-
oratory parameters, meaning the decreased hemoglobin level, he-
matocrit, and cholesterol. On the other hand, a study describing the
African American population found that obesity is a risk factor of
cyst formation (p ¼ 0.06) [33]. Another meta-analysis of our
workgroup described fatty liver disease as a further risk factor of
cyst development [34]. In the OLD-P group, biliary etiology is less
common with lower levels of liver function tests, such as total
bilirubin, GOT, GPT, and GGT. The exhaustion of exocrine functions
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lower levels of on admission amylase and lipase, due to the
decreased amount of acinus cells in the case of a chronic inflam-
mation, which is also supported by the fact, that the difference
disappears once the chronic pancreatic cases and recurrent acute
pancreatic cases are excluded from the analysis. Thus, the shrinkage
of the pancreas, thus the decreased amount of acinus cells in the
cases of recurring or chronic inflammation, were formerly
described by Steve et al. [35], supporting this idea. The fact that new
pseudocysts are associated with increased white blood cell count
and lactate dehydrogenase correlates with the effect of pseudocyst
on the severity.
In contrast, increased hemoglobin, hematocrit, blood urea ni-
trogen, and creatinine foreshadow the possibility of dehydration on
admission. The significantly higher risk of systemic complications
in NEW-P is partly driven by acute kidney injury, reflected by the
significantly elevated blood urea nitrogen and creatinine levels.
More diabetogenic state of the NEW-P group is presented in the
elevated level of on admission glucose. While Akgül et al. found
that a lower serum calcium level may be a predictive factor for
developing pancreatic pseudocysts after an AP attack [9], our
analysis did not find such association. On the other hand, we sup-
port the findings of Cui et al. regarding increased LDH and CRP
levels in the cases of the pancreatic pseudocyst. However, we found
on admission laboratory parameters to be associated with the
condition, not the 48-h value as the mentioned study did.
Interventions on the pancreatic pseudocysts should be carried
out if it causes any symptom to the patient or in the case of the
infected fluid collection according to the European Society of
Gastrointestinal Endoscopy (ESGE) [36]. While interventions may
vary, they should rely on local expertise and the location of the fluid
collection. Although each treatment modality has its important
undebatable role, minimally invasive techniques, including endo-
scopic and percutaneous drainage, should be preferred. According
to our recent meta-analysis, if multiple interventional modalities
can be applied, endoscopic intervention should be preferred [37]. In
our analysis, less than one-third of the patient required interven-
tion. Still, this proportion was higher in the OLD-P group, where
endoscopic interventions were carried out in more cases, compared
to percutaneous or surgical drainage. Interestingly percutaneous
drainage was more common in the NEW-P group, which might be
due to the suspected benefit of this intervention according to the
cyst's localization. However, our analysis did not investigate this
question.
Limitations of our analysis
Our study has several limitations. Although all data were
collected prospectively, clinical questions were post hoc defined.
Cases were included in the analysis with imaging reports from
several centers from several radiologists. We aimed to minimize
these limitations by uniform data collection forms. The imaging
modalities included both ultrasound and computer tomography,
which have different sensitivity and specificity for pancreatic
pseudocysts. Furthermore, the criteria, we implied considering our
cohort's grouping were based on empirical expert opinion since we
believe that forming a new pseudocyst is unlikely to happen in the
first four days.
Implications for research
While our analysis highlighted many aspects regarding pseu-
docysts, a prospective observational study focusing on the risk
factors of pseudocyst development and prognostic factors of the
disease course of patients with diagnosed pseudocysts should be11proposed to achieve clearer insight into this complication of AP.
Implications for practice
Based on our findings, we encourage the nonmandatory use of
the timeframes of the revised Atlanta classification for the diag-
nosis of the pancreatic pseudocyst to allow earlier diagnosis and
possible earlier treatment. Furthermore, considering the toxic and
evoking effects of alcohol and smoking on cyst formation, cessation
programs should be emphasized inmedical therapy for AP patients.
Considering the severity and possible organ failures, newly diag-
nosed pseudocysts require more attention as they indicate worse
outcomes.
Conclusions
Newly developing pseudocysts are associated with a more se-
vere disease course and increased length of hospitalization. Most of
the new pseudocysts develop within two weeks. Pre-existing
pseudocysts are associated with higher alcohol consumption and
smoking. The fact that CP is more frequently associated with a pre-
existing pseudocyst, these patients need closer attention after AP.
Funding
The research was supported by Project Grants (K131996 to PH,
FK131864 to AM, FK124632 to BCN, K128222 to LC and K120335 to
TT) of the National Research Development and Innovation Office,
and Economic Development and Innovation Operative Programme
Grant (GINOP 2.3.2-15-2016-00048, and GINOP-2.3.2-15-2016-
00015 e I-KOM to PH), a Human Resources Development Opera-
tional Programme Grant (EFOP-3.6.2-16-2017-00006 to PH), Janos
Bolyai Research Scholarship of the Hungarian Academy of Sciences.
Author contributions
Er}oss B and Hegyi P conceptualized and designed the study in
cooperation with Szentesi A, Vincze A, Parniczky A, and Szako L;
Mosztbacher D, Vincze A, Takacs T, Czako L, Izbeki F, Gajdan L,
Dunas-Varga V, Hamvas J, Papp M, Feher K E, Varga M, Mickevicius
A, Miko A and T€or€ok I contributed to the data collection from their
respective center; Tinusz B, V€orhendi N, and Szako L performed
data extraction on patients frommultiple centers; Tinusz B, Vancsa
S, Juhasz MF, Ocskay K and Hegyi JP, conducted the quality
assessment; Szako L and Er}oss B wrote the article; Miseta A, Ver-
eczkei A, Miko A, Szentesi A, Parniczky A, and Hegyi P provided
valuable feedback after critically reviewing the first drafts of the
manuscript. Faluhelyi N and Farkas O assessed the imaging exam-
inations. Gede N and Varadi A performed the statistical analysis. All
the authors reviewed and approved the final manuscript for pub-
lication, while providing critical input.
STROBE 2007 checklist statement
The authors have read the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) 2007 Checklist,
and the manuscript was prepared and revised accordingly [1].
Declaration of competing interest
The authors declare no competing interests.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
L. Szako, N. Gede, A. Varadi et al. Pancreatology xxx (xxxx) xxxhttps://doi.org/10.1016/j.pan.2021.05.007.
References
[1] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observational studies. BMJ
(Clinical research ed) 2007;335(7624):806e8.
[2] Imrie CW, Buist LJ, Shearer MG. Importance of cause in the outcome of
pancreatic pseudocysts. Am J Surg 1988;156(3 Pt 1):159e62.
[3] Maringhini A, Uomo G, Patti R, Rabitti P, Termini A, Cavallera A, et al. Pseu-
docysts in acute nonalcoholic pancreatitis: incidence and natural history. Dig
Dis Sci 1999;44(8):1669e73.
[4] Barthet M, Bugallo M, Moreira LS, Bastid C, Sastre B, Sahel J. Management of
cysts and pseudocysts complicating chronic pancreatitis. A retrospective study
of 143 patients. Gastroenterol Clin Biol 1993;17(4):270e6.
[5] Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al.
Burden of gastrointestinal disease in the United States: 2012 update.
Gastroenterology 2012;143(5):1179e87. e3.
[6] Szentesi A, Toth E, Balint E, Fanczal J, Madacsy T, Laczko D, et al. Analysis of
research activity in gastroenterology: pancreatitis is in real danger. PloS One
2016;11(10):e0165244.
[7] Parniczky A, Kui B, Szentesi A, Balazs A, Sz}ucs A, Mosztbacher D, et al. Pro-
spective, multicentre, nationwide clinical data from 600 cases of acute
pancreatitis. PloS One 2016;11(10):e0165309.
[8] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al.
Classification of acute pancreatitis–2012: revision of the Atlanta classification
and definitions by international consensus. Gut 2013;62(1):102e11.
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